Get the Stockscreener App
16.26
18.00%
2.48
Pre-market:
24.38
8.12
+49.94%
Avalo Therapeutics Inc stock is traded at $16.26, with a volume of 3.80M.
It is up +18.00% in the last 24 hours and down -8.45% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$13.78
Open:
$13.87
24h Volume:
3.80M
Relative Volume:
5.18
Market Cap:
$370.54M
Revenue:
$59,000
Net Income/Loss:
$-78.26M
P/E Ratio:
-2.6671
EPS:
-6.0964
Net Cash Flow:
$-51.46M
1W Performance:
+26.44%
1M Performance:
-8.45%
6M Performance:
-1.16%
1Y Performance:
+223.90%
1-Day Range:
$13.87
$16.30
1-Week Range:
$12.51
$16.30
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
16.26 | 370.54M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why - Benzinga
Avalo Therapeutics prices $375 million stock offering By Investing.com - Investing.com Australia
Avalo Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Avalo prices $375M sale to fund drug development through Phase 3 data - Stock Titan
Avalo Therapeutics announces pricing of $375 million public offering at $17.75 per share - marketscreener.com
Avalo Therapeutics Announces Pricing of $375 Million Public Offering - GlobeNewswire
Avalo Therapeutics Reports Strong Phase 2 Hidradenitis Data - TipRanks
Avalo’s abdakibart meets primary endpoint in hidradenitis trial By Investing.com - Investing.com Australia
Avalo Therapeutics launches public stock offering By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) prospectus: stock and pre-funded warrants offering with Phase 2 data - Stock Titan
Avalo Therapeutics stock surges 35% on positive trial data - Investing.com
Avalo Therapeutics launches public stock offering - Investing.com
Avalo launches stock sale to fund Phase 3 abdakibart work - Stock Titan
Avalo's skin disease drug beat placebo in Phase 2, heads to Phase 3 - Stock Titan
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa - The Manila Times
Strong Phase 2 HS data for abdakibart boosts Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
Avalo Therapeutics Achieves Positive Topline Results in - GlobeNewswire
This Avalo Therapeutics analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
Jennison Associates LLC Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock - MarketBeat
Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock - MarketBeat
Avalo Therapeutics (AVTX) CFO trims stake in 10b5-1 share sales - Stock Titan
Insider sale of 16,915 restricted shares (AVTX) - Stock Titan
Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform By Investing.com - Investing.com Australia
Moody Aldrich Partners LLC Buys Shares of 133,231 Avalo Therapeutics, Inc. $AVTX - MarketBeat
Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform - Investing.com
AVTX Q1'26 Earnings: EPS estimate is (1.18) USD - TradingView
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics (AVTX) Secures Milestone Buyout Option with A - GuruFocus
Avalo Therapeutics enters milestone buyout option agreement on April 26SEC filing - marketscreener.com
Avalo Therapeutics Restructures AlmataBio Milestone Payment Obligations - TipRanks
Avalo Therapeutics Purchases Optional Milestone Buyout - The Manila Times
Avalo Therapeutics (NASDAQ: AVTX) adopts optional milestone buyout structure - Stock Titan
Avalo pays $2.25M for 90-day option to replace $15M payout - Stock Titan
Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Avalo Therapeutics (AVTX) - The Globe and Mail
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Avalo (AVTX) Stock: Buy, Sell, Hold? (Smart Money Outflows) 2026-04-15Trend Signals - Cổng thông tin điện tử tỉnh Lào Cai
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Increase in Short Interest - MarketBeat
AVTX Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Short Squeeze: Can Avalo Therapeutics Inc grow without external funding2026 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Breakout Move: Is Avalo Therapeutics Inc a potential multi baggerWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Avalo Therapeutics (NASDAQ: AVTX) sets 2026 virtual meeting and ESPP changes - Stock Titan
Death Cross: Will Avalo Therapeutics Inc be affected by tariffsWeekly Loss Report & Daily Profit Focused Screening - baoquankhu1.vn
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
AVTX: Wolfe Research Initiates Coverage with 'Outperform' Rating - GuruFocus
Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48 - Moomoo
Mittie Doyle Sells 3,970 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock - MarketBeat
Aug Closing: Is Avalo Therapeutics Inc undervalued by DCF analysis2026 Weekly Recap & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Avalo Therapeutics: chief medical officer Doyle Mittie sells $71k in AVTX - Investing.com Canada
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):